Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2023 08:00 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
October 30, 2023 08:00 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

- IND filing for CX-801 anticipated by the end of 2023 - SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of...
October 18, 2023 16:30 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

- CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload - - Preclinical data demonstrate a...
September 05, 2023 16:05 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
August 10, 2023 16:05 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
August 08, 2023 16:15 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

- CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 - - IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b)...
August 01, 2023 08:00 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
July 20, 2023 09:00 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
July 17, 2023 08:00 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the...
June 30, 2023 08:00 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

- Financing is expected to extend cash runway into the 2nd half of 2025 based on current operating plans, enabling the Company to reach multiple clinical milestones - - $30 million initial investment...